Document is current
Any future updates will be listed below
-
Authors
Penack, Olaf https://orcid.org/0000-0003-4876-802X
Abouqateb, Mouad
Peczynski, Christophe
Boreland, William
Kröger, Nicolaus https://orcid.org/0000-0001-5103-9966
Zeiser, Robert https://orcid.org/0000-0001-6565-3393
Ciceri, Fabio
Schroeder, Thomas
Dreger, Peter https://orcid.org/0000-0002-7429-8570
Passweg, Jakob https://orcid.org/0000-0001-7092-3351
Schetelig, Johannes
Stelljes, Matthias
Blau, Igor Wolfgang
Franke, Georg-Nikolaus https://orcid.org/0000-0001-8239-002X
Riesner, Katarina
Schoemans, Hélène https://orcid.org/0000-0002-7568-8239
Moiseev, Ivan
Peric, Zinaida
- License Information
-
More Information
Article History
Received: 10 April 2024
Revised: 12 June 2024
Accepted: 14 June 2024
First Online: 25 June 2024
Competing interests
: HS: personal fees from Incyte, Janssen, Novartis, Sanofi, and from the Belgian Hematological Society (BHS), as well as research grants from Novartis and the BHS, all paid to her institution and not directly related to this work. She has also received non-financial support (travel grants) from Gilead, Pfizer, the EBMT (European Society for Blood and Marrow transplantation), and the CIBMTR (Center for International Bone Marrow Transplantation Research). OP has no COIs directly related to this work. OP has received honoraria or travel support from Gilead, Jazz, MSD, Neovii, Novartis, Pfizer, and Therakos. He has received research support from Incyte and Priothera. He is member of advisory boards to Equillium Bio, Jazz, Gilead, Novartis, MSD, Omeros, Priothera, Sanofi, Shionogi, and SOBI. RZ: Honorarium from Novartis, Incyte, MNK (Therakos), medac, Neovii. The remaining authors declare no competing interests.
: The study was approved by the EBMT review board. Patients had to sign an informed consent document that permitted sharing of clinical data according to national rules.
